November 16, 2026: MaaT Pharma Reports Financial Results for the Third Quarter 2026

Date : November 16, 2026

MaaT Pharma Reports Financial Results for the Third Quarter 2026

  • Revenues of EUR 0.5 million in the third quarter of 2026 and EUR 1.6 million year-to-date, derived from the Early Access Program
  • As of September 30, 2026, cash and cash equivalents were EUR 10.1 million, not including the EUR 3.7 million 2025 Research Tax Credit, received by the Company in October 2026
  • Cash runway estimated through the end of December 2026, based on the Company’s current operating plan and financial obligations
  • The Company continues to actively explore financing opportunities from investors and strategic partnerships

 

Lyon, France, November 16, 2026 – 6:00 pm CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), a late-stage clinical biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today reported its cash position and revenues as of September 30, 2026.

Cash position1 

  • As of September 30, 2026, total cash and cash equivalents were EUR 10.1 million (as compared to EUR 24.9 million as of December 31, 2025).
  • Taking into account the EUR 3.7 million 2025 Research Tax Credit received in October 2026, the Company estimates that its existing cash resources will fund operations through the end of December 2026, based on its current operating plan and financial obligations.

 

Revenues in Q3 20261

  • MaaT Pharma reported revenues of EUR 0.5 million for the third quarter of 2026, and revenues of EUR 1.6 million for the first nine months of 2026.
  • Since January 2026 and following the transition of the EAP program to Clinigen, MaaT Pharma has been selling the product to Clinigen, which then supplies hospitals in Europe. As a result, revenues generated by the Company are now based on the financial terms of the licensing agreement. Consequently, the net revenue reported by MaaT Pharma for the first nine months of 2026, based on transfer price and royalties, was EUR 1.6 million, and would have been EUR 3.3 million pre-transition, broadly stable compared with EUR 3.4 million in the first nine months of 2025.

 

Upcoming conferences*

  • November 16-18, 2026: ESMO AI Conference in Berlin, Germany
  • November 18-20, 2026: SFGM-TC Annual Congress, Marseille, France
  • November 25-26, 2026: The AI – Microbiome Bootcamp by EMIH, Aix-en-Provence, France
  • December 12-15, 2026: ASH 68th Annual Meeting in New Orleans, Louisiana, USA

*Indicative calendar that may be subject to change.

[1] unaudited financial results

—

About MaaT Pharma
MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021.

Forward-looking Statements
All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “aim”, “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.

Acting Chief Scientific Officer

Sheri Simmons

Sheri Simmons, Ph.D., is Acting Chief Scientific Officer at MaaT Pharma. Sheri brings extensive experience in biotechnology, particularly in the microbiome field, having held scientific leadership positions at Seres Therapeutics, Johnson & Johnson’s Microbiome Solutions team, and most recently at Seed Health, a leading probiotics company. In her role, she strengthens the Company’s scientific leadership, overseeing preclinical research, AI/data initiatives, and supporting efforts toward the Marketing Authorization Application of Xervyteg® in aGvHD.

Sheri holds a PhD in Biological Oceanography from the Massachusetts Institute of Technology (MIT) and completed an A.B. in Ecology & Evolutionary Biology at Princeton University, graduating summa cum laude and as a Phi Beta Kappa member, receiving one of six awards for the best senior thesis in the sciences. Sheri holds a PhD in Biological Oceanography from the Massachusetts Institute of Technology (MIT) and completed an A.B. in Ecology & Evolutionary Biology at Princeton University, graduating summa cum laude and as a Phi Beta Kappa member, receiving one of six awards for the best senior thesis in the sciences.

CEO and co-founder

Hervé Affagard

Hervé Affagard is the CEO and co-founder of MaaT Pharma. For the past 15 years, Hervé has been an intra/entrepreneur in the healthcare industry, after starting his career in IT in the steel industry. In late 2014, Hervé co-founded the company alongside Dr. Joël Doré, author of nearly 500 publications, and
one of the world’s most cited authors in the microbiome sphere today, after a professional career that spanned multiple industries. Hervé has led MaaT Pharma’s development from its early concept in 2013 and has been at the forefront of the development of the microbiome healthcare ecosystem in France and Europe. In January 2022, Hervé has been elected President of Allliance Promotion Microbiote, an organization founded in 2021 to support the microbiome sector development in France.

Engineer, MBA